GlaxoSmithKline plc has taken that old adage to heart. Undeterred by the previous failure in Phase II trials of a candidate antidepressant it had licensed from the Danish firm NeuroSearch A/S, it has returned to the well in search of a fresh source of triple-action compounds that block reuptake of the neurotransmitters dopamine, noradrenaline and serotonin. (Bioworld Today)

GlaxoSmithKline plc has taken that old adage to heart. Undeterred by the previous failure in Phase II trials of a candidate antidepressant it had licensed from the Danish firm NeuroSearch A/S, it has returned to the well in search of a fresh source of triple-action compounds that block reuptake of the neurotransmitters dopamine, noradrenaline and serotonin. (Bioworld Today)